Literature DB >> 16990083

Patient characteristics and patterns of drug use for sleep complaints in the United States: analysis of National Ambulatory Medical Survey data, 1997-2002.

Robert J Morlock1, Maudrene Tan, David Y Mitchell.   

Abstract

OBJECTIVE: The aims of this work were to characterize ambulatory patients in the United States presenting with primary or secondary insomnia complaints and resultant diagnoses, and to describe the characteristics of patients treated with medications commonly used for sleep complaints.
METHODS: Data from the National Ambulatory Medical Care Survey for the years 1997 through 2002 were analyzed. Data were stratified by patient characteristics, physician specialty, resulting diagnosis, and medications prescribed or provided. The unit of analysis was the individual patient visit; statistical comparisons were made using the chi(2) test for categorical variables and the Rao-Scott design-adjusted chi(2) test for comparisons of patient age groups. P<0.05 was the criterion for statistical significance. Cells containing < 30 observations were not included in the statistical analysis.
RESULTS: The data included 147,945 patient visit records; rates of physician response to the survey ranged from 62.9% in 1999 to 70.4% in 2002. Based on this sample, it was projected that 30 million office visits involved insomnia complaints over the 6-year period from 1997 to 2002 throughout the United States. With a total of 4.9 billion physician visits projected for that time period, 0.6% of visits were insomnia related. Women were 1.5 times more likely to have insomnia-related visits (P<0.001). Overall, the greatest proportion of insomnia patients of both sexes was between the ages of 18 and 64 years (P<0.001). Sleep difficulties were most frequently attributed to organic disorders, depression and/or anxiety, and primary insomnia (55.8%, 27.3%, and 9.8%, respectively; P<0.001). The most frequently prescribed or recommended medications were zaleplon/zolpidem and trazodone (28.5% and 32.0%, respectively; P<0.001). Zaleplon and zolpidem were most frequently used for patients with organic diagnoses and those aged < or =65 years (33.2% and 29.8%; P<0.001).
CONCLUSIONS: Demographics of patients with insomnia and their diagnoses from 1999 to 2002 remained stable, but the use of medications changed predictably as newer agents became available.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990083     DOI: 10.1016/j.clinthera.2006.07.008

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  22 in total

1.  GPs' management strategies for patients with insomnia: a survey and qualitative interview study.

Authors:  Hazel Everitt; Lisa McDermott; Geraldine Leydon; Harvey Yules; David Baldwin; Paul Little
Journal:  Br J Gen Pract       Date:  2014-02       Impact factor: 5.386

2.  Sedative medication use: prevalence, risk factors, and associations with body mass index using population-level data.

Authors:  Nicholas T Vozoris; Richard S Leung
Journal:  Sleep       Date:  2011-07-01       Impact factor: 5.849

3.  National use of prescription medications for insomnia: NHANES 1999-2010.

Authors:  Suzanne M Bertisch; Shoshana J Herzig; John W Winkelman; Catherine Buettner
Journal:  Sleep       Date:  2014-02-01       Impact factor: 5.849

4.  The hypnotic zolpidem increases the synchrony of BOLD signal fluctuations in widespread brain networks during a resting paradigm.

Authors:  Stephanie C Licata; Lisa D Nickerson; Steven B Lowen; George H Trksak; Robert R Maclean; Scott E Lukas
Journal:  Neuroimage       Date:  2013-01-05       Impact factor: 6.556

Review 5.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

6.  How does gestational diabetes affect postpartum contraception in nondiabetic primiparous women?

Authors:  Hind A Beydoun; May A Beydoun; Hala Tamim
Journal:  Contraception       Date:  2008-12-11       Impact factor: 3.375

7.  Racial differences in sleep medication use: a cross-sectional study of the Johnston County Osteoarthritis Project.

Authors:  Kelli D Allen; Jordan B Renner; Brenda DeVellis; Charles G Helmick; Joanne M Jordan
Journal:  Ann Pharmacother       Date:  2008-07-15       Impact factor: 3.154

8.  Trends in outpatient visits for insomnia, sleep apnea, and prescriptions for sleep medications among US adults: findings from the National Ambulatory Medical Care survey 1999-2010.

Authors:  Earl S Ford; Anne G Wheaton; Timothy J Cunningham; Wayne H Giles; Daniel P Chapman; Janet B Croft
Journal:  Sleep       Date:  2014-08-01       Impact factor: 5.849

9.  Retrospective population cohort study on hip fracture risk associated with zolpidem medication.

Authors:  Fang-Yu Lin; Pei-Chun Chen; Chun Hui Liao; Yow-Wen Hsieh; Fung-Chang Sung
Journal:  Sleep       Date:  2014-04-01       Impact factor: 5.849

10.  A therapeutic dose of zolpidem has limited abuse-like effects in drug-naïve females: a pilot study.

Authors:  Stephanie C Licata; David M Penetar; Steven Dunlap; Scott E Lukas
Journal:  Eur J Pharmacol       Date:  2008-09-22       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.